PARP inhibitors

  • August 15, 2020  

    Key Studies in Metastatic Breast Cancer From ASCO 2020 Bookmark

    George Lundberg, MD

    Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

    This year’s virtual meeting of the American Society of Clinical Oncology (ASCO) featured five important studies on metastatic breast cancer, as outlined in this video.

    Go to full article and video published by Medscape.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • May 12, 2020  

    Pancreatic Cancer Survival Rates: What Do They Really Mean?

    Lola Rahib, PhD

    The American Cancer Society estimates that in 2020, 57,600 people in the U.S. will be diagnosed with pancreatic cancer and 47,050 will die from the disease. But not everyone’s pancreatic cancer is the same. Understanding what survival rates mean—and which factors can impact them—could help you navigate your or your loved one’s disease. What is the five-year relative survival rate for pancreatic cancer? In… Read more »

  • December 13, 2019  

    PARP Inhibitors Center Stage for Ovarian Cancer Bookmark

    George Lundberg, MD

    Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

    Drugs known as PARP inhibitors can improve progression-free survival (PFS) in many patients with advanced ovarian cancers.

    Go to full article published by Medscape.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019  

    Ovarian Cancer: Is This the Beginning of the End? Bookmark

    George Lundberg, MD

    Article from Healio curated by Editor in Chief George Lundberg, MD, who notes: 

    This piece discusses recent insights into ovarian cancer, including the fact that this type of cancer sometimes originates in the fallopian tube, and that drugs known as PARP inhibitors show great therapeutic promise.

    Go to full article published by Healio.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • September 18, 2018  

    Biomarkers, PARP Inhibitors Vital for Personalized Treatment in Breast Cancer Subtypes Bookmark

    Emma Shtivelman, PhD

    Excerpt from OncLive:

    “Developing predictive biomarkers will be key to treating patients with triple-negative breast cancer (TNBC), especially when choosing a targeted therapy, said Banu K. Arun, MD.

    “In a presentation during the 2018 OncLive® State of the Science Summit™ on Breast Cancer, Arun said there is evidence that PARP inhibitors as well as immunotherapy in combination with various agents may be effective in women with TNBC and BRCA1-related breast cancers, but the science isn’t there yet.”

    Go to full article published by OncLive on Aug 29, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • October 4, 2017  

    New Trends in Pre-Surgery Treatments for Breast Cancer

    Emma Shtivelman, PhD

    Non-metastatic breast cancers are most often treated with surgery, but if the tumors are fairly large, or involve nearby lymph nodes, neoadjuvant (pre-operative) treatments with chemotherapy (NAC) are done first. NAC often reduces the tumor size and kills cancer cells in lymph nodes, if present, prior to surgery, improving the outcome. The best possible result of neoadjuvant treatment is pCR (pathologic compete response), when… Read more »